24/7 Market News Snapshot 28 May, 2025 – Spero Therapeutics, Inc. Common Stock (NASDAQ:SPRO)

May 28, 2025

DENVER, Colo., 28 May, 2025 (www.247marketnews.com) – (NASDAQ:SPRO) are discussed in this article.
Spero Therapeutics, Inc. (NASDAQ:SPRO) has witnessed a remarkable surge in its stock value, currently trading at $2.007, reflecting a 194.28% increase from its previous closing price of $0.682. This significant rise, accompanied by a trading volume of 20.06 million shares, underscores heightened investor optimism surrounding the company. The surge appears to be driven by promising developments in Spero’s quest to innovate therapies, particularly in light of recent advancements in the treatment of complicated urinary tract infections (cUTIs).

In a pivotal breakthrough, Spero and its partner GSK plc announced the successful completion of the Phase 3 PIVOT-PO trial for tebipenem HBr, an investigational oral carbapenem antibiotic. This trial, which involved 1,690 patients, not only met its primary endpoint but also led to an early cessation for efficacy due to its significant positive results. Tebipenem HBr has shown non-inferiority to the intravenous treatment imipenem-cilastatin, presenting a potential shift in managing cUTIs, particularly given the growing concerns over multi-drug-resistant bacteria.

Highlighting the urgency of the situation, Spero’s CEO, Esther Rajavelu, emphasized that tebipenem HBr could revolutionize treatment options and reduce healthcare costs associated with hospitalizations. GSK’s Chief Scientific Officer, Tony Wood, also noted the necessity for effective oral antibiotics to combat the rising threat of drug-resistant infections. The anticipated regulatory filing with the U.S. Food and Drug Administration is projected for the second half of 2025, marking a critical step towards making this innovative treatment widely available. Full results from the trial will be shared at an upcoming scientific congress and published in a peer-reviewed journal, further affirming Spero’s dedication to advancing healthcare solutions.

Related news for (SPRO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.